Volume 93 Issue 48 | p. 14
Issue Date: December 7, 2015

Cover Stories

2015 Pharma Year In Review

Drug pricing, appetite for acquisitions, and new technology make headlines in 2015
Department: Business
Keywords: pharmaceuticals, biotech, M&A, immuno-oncology, drug prices

With just weeks remaining in 2015, C&EN is taking stock of the biggest news and trends in the pharmaceutical industry. The following pages feature the stories that had the most impact—positive or negative—on companies, researchers, investors, and patients.

[+]Enlarge
Credit: Shutterstock
A series of pill bottles ascending in height.
 
Credit: Shutterstock

We take note of the themes that consistently found their way into the headlines, and even the presidential race, this year: the rapidly rising cost of drugs, the pressure for big companies to get even bigger, the promise and peril of the gene-editing technology CRISPR, and the great potential to harness the immune system to quash cancer.

We look at the launch of well-funded biotech companies, many of which were jockeying for lab space in Boston, a city that is emerging as the center of the life sciences universe. And we explore the financial trends that impacted the top 10 drug firms, a list that will get reshuffled if Pfizer’s recently announced deal to acquire Allergan is consummated next year.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society
Leave A Comment